TriangleNCT01771107 · OUTCOME
CD8 Counts
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- cells/µL
- Interval / dispersion
- Inter-Quartile Range
- Time frame
- 5 months
What was measured
Absolute CD8 counts at cycle 5
Analysis population: Participants with absolute CD8 counts at cycle 5
Groups in this outcome
Phase I - Brentuximab 1.2 mg/kg
Patients receive doxorubicin hydrochloride IV, vinblastine sulfate IV, and dacarbazine IV on days 1 and 15. Patients also receive brentuximab vedotin IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Brentuximab Vedotin: Given IV Dacarbazine: Given IV Doxorubicin Hydrochloride: Given IV Pharmacological Study: Correlative studies Vinblastine: Given IV
Phase II - Brentuximab 1.2 mg/kg
Patients receive doxorubicin hydrochloride IV, vinblastine sulfate IV, and dacarbazine IV on days 1 and 15. Patients also receive brentuximab vedotin IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Brentuximab Vedotin: Given IV Dacarbazine: Given IV Doxorubicin Hydrochloride: Given IV Pharmacological Study: Correlative studies Vinblastine: Given IV
| Group | Source count |
|---|---|
| Phase I - Brentuximab 1.2 mg/kg | 6 |
| Phase II - Brentuximab 1.2 mg/kg | 26 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Phase I - Brentuximab 1.2 mg/kg | 719.5 | Not reported | 596 | 883 | Not reported |
| Phase II - Brentuximab 1.2 mg/kg | 666.5 | Not reported | 470 | 954 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 596
- upper Limit
- 883
- value
- 719.5
- group Id
- OG001
- lower Limit
- 470
- upper Limit
- 954
- value
- 666.5
- denoms
- counts
- group Id
- OG000
- value
- 6
- group Id
- OG001
- value
- 26
- units
- Participants
- description
- Absolute CD8 counts at cycle 5
- dispersion Type
- Inter-Quartile Range
- groups
- description
- Patients receive doxorubicin hydrochloride IV, vinblastine sulfate IV, and dacarbazine IV on days 1 and 15. Patients also receive brentuximab vedotin IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Brentuximab Vedotin: Given IV Dacarbazine: Given IV Doxorubicin Hydrochloride: Given IV Pharmacological Study: Correlative studies Vinblastine: Given IV
- id
- OG000
- title
- Phase I - Brentuximab 1.2 mg/kg
- description
- Patients receive doxorubicin hydrochloride IV, vinblastine sulfate IV, and dacarbazine IV on days 1 and 15. Patients also receive brentuximab vedotin IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Brentuximab Vedotin: Given IV Dacarbazine: Given IV Doxorubicin Hydrochloride: Given IV Pharmacological Study: Correlative studies Vinblastine: Given IV
- id
- OG001
- title
- Phase II - Brentuximab 1.2 mg/kg
- param Type
- MEDIAN
- population Description
- Participants with absolute CD8 counts at cycle 5
- reporting Status
- POSTED
- time Frame
- 5 months
- title
- CD8 Counts
- type
- SECONDARY
- unit Of Measure
- cells/µL
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice